Differentially expressed circulating microRNAs in the development of acute diabetic Charcot foot

Aim: Charcot foot (CF) is a rare complication of Type 2 diabetes (T2D). Materials & methods: We assessed circulating miRNAs in 17 patients with T2D and acute CF (G1), 17 patients with T2D (G2) and equivalent neuropathy and 17 patients with T2D without neuropathy (G3) using the high-throughput miRNA expression profiling. Results: 51 significantly deregulated miRNAs were identified in G1 versus G2, 37 in G1 versus G3 and 64 in G2 versus G3. Furthermore, we demonstrated that 16 miRNAs differentially expressed between G1 versus G2 could be involved in osteoclastic differentiation. Among them, eight are key factors involved in CF pathophysiology. Conclusion: Our data reveal that CF patients exhibit an altered expression profile of circulating miRNAs.

[1]  P. Codoñer-Franch,et al.  Molecular aspects of diabetes mellitus: Resistin, microRNA, and exosome , 2018, Journal of cellular biochemistry.

[2]  Talal K. Talal,et al.  Circulating microparticles in acute diabetic Charcot foot exhibit a high content of inflammatory cytokines, and support monocyte-to-osteoclast cell induction , 2017, Scientific Reports.

[3]  A. Jayyousi,et al.  Macrovascular Complications in Patients with Diabetes and Prediabetes , 2017, BioMed research international.

[4]  G. Calin,et al.  Cell‐to‐cell communication: microRNAs as hormones , 2017, Molecular oncology.

[5]  Bin Wang,et al.  MicroRNA-144-3p inhibits bone formation in distraction osteogenesis through targeting Connexin 43 , 2017, Oncotarget.

[6]  Sik Yoon,et al.  HIF-1α:CRAT:miR-144-3p axis dysregulation promotes osteoarthritis chondrocyte apoptosis and VLCFA accumulation , 2017, Oncotarget.

[7]  Yong Wang,et al.  Long non-coding RNA MALAT1 for promoting metastasis and proliferation by acting as a ceRNA of miR-144-3p in osteosarcoma cells , 2017, Oncotarget.

[8]  Guosong Jiang,et al.  LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. , 2017, Cancer letters.

[9]  G. Lip,et al.  Novel Risk Markers and Risk Assessments for Cardiovascular Disease , 2017, Circulation research.

[10]  Quanyan Liu,et al.  Upregulation of SNHG6 regulates ZEB1 expression by competitively binding miR-101-3p and interacting with UPF1 in hepatocellular carcinoma. , 2016, Cancer letters.

[11]  R. Freeman,et al.  Diabetic Neuropathy: A Position Statement by the American Diabetes Association , 2016, Diabetes Care.

[12]  C. Suh,et al.  Circulating hsa‐miR‐30e‐5p, hsa‐miR‐92a‐3p, and hsa‐miR‐223‐3p may be novel biomarkers in systemic lupus erythematosus , 2016, HLA.

[13]  Zheng Zhang,et al.  miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy , 2016, Molecular and Cellular Endocrinology.

[14]  A. Baierl,et al.  Circulating microRNA Signatures in Patients With Idiopathic and Postmenopausal Osteoporosis and Fragility Fractures. , 2016, The Journal of clinical endocrinology and metabolism.

[15]  A. Schneeweiss,et al.  Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. , 2016, Carcinogenesis.

[16]  Lian‐Wen Qi,et al.  Autophagy inhibition of hsa-miR-19a-3p/19b-3p by targeting TGF-β R II during TGF-β1-induced fibrogenesis in human cardiac fibroblasts , 2016, Scientific Reports.

[17]  N. Petrova,et al.  Acute Charcot neuro‐osteoarthropathy , 2016, Diabetes/metabolism research and reviews.

[18]  Yigang Li,et al.  The role of miR-19b in the inhibition of endothelial cell apoptosis and its relationship with coronary artery disease , 2015, Scientific Reports.

[19]  A. Rafii,et al.  Epigenetics and Cardiovascular Disease in Diabetes , 2015, Current Diabetes Reports.

[20]  K. Arga,et al.  Tissue-Specific Molecular Biomarker Signatures of Type 2 Diabetes: An Integrative Analysis of Transcriptomics and Protein-Protein Interaction Data. , 2015, Omics : a journal of integrative biology.

[21]  Jinxiang Zhang,et al.  Upregulation of miR‐362‐3p Modulates Proliferation and Anchorage‐Independent Growth by Directly Targeting Tob2 in Hepatocellular Carcinoma , 2015, Journal of cellular biochemistry.

[22]  T. Herman,et al.  Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells , 2015, BMC Genomics.

[23]  R. Couto,et al.  Risk factors for Charcot foot. , 2015, Archives of endocrinology and metabolism.

[24]  A. Tuttolomondo,et al.  Diabetic Foot Syndrome as a Possible Cardiovascular Marker in Diabetic Patients , 2015, Journal of diabetes research.

[25]  Dao-zhong Chen,et al.  Influence of microRNA-related polymorphisms on clinical outcomes in coronary artery disease. , 2015, American journal of translational research.

[26]  A. Tuttolomondo,et al.  Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes. , 2015, World journal of orthopedics.

[27]  S. Luo,et al.  Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study , 2014, Nature Methods.

[28]  S. Wang,et al.  Molecular Pathways and Functional Analysis of miRNA Expression Associated with Paclitaxel-Induced Apoptosis in Hepatocellular Carcinoma Cells , 2013, Pharmacology.

[29]  Jan Lubinski,et al.  MiRNA‐362‐3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer , 2013, International journal of cancer.

[30]  David J. Galas,et al.  Comparing the MicroRNA Spectrum between Serum and Plasma , 2012, PloS one.

[31]  M. Marre,et al.  Cause-specific mortality in diabetes: recent changes in trend mortality , 2012, European journal of preventive cardiology.

[32]  G. Bouma,et al.  Cell-Secreted Vesicles in Equine Ovarian Follicular Fluid Contain miRNAs and Proteins: A Possible New Form of Cell Communication Within the Ovarian Follicle1 , 2012, Biology of reproduction.

[33]  M. Michael,et al.  Circulating microRNA expression is reduced in chronic kidney disease. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  Lee C. Rogers,et al.  The Charcot Foot in Diabetes , 2011, Diabetes Care.

[35]  E. Kroh,et al.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.

[36]  M. Edmonds,et al.  Number of Circulating CD14-Positive Cells and the Serum Levels of TNF-α Are Raised in Acute Charcot Foot , 2011, Diabetes Care.

[37]  Jessica A. Weber,et al.  The microRNA spectrum in 12 body fluids. , 2010, Clinical chemistry.

[38]  Jessica A. Weber,et al.  Export of microRNAs and microRNA-protective protein by mammalian cells , 2010, Nucleic acids research.

[39]  A. Bergamini,et al.  Proinflammatory Modulation of the Surface and Cytokine Phenotype of Monocytes in Patients With Acute Charcot Foot , 2009, Diabetes Care.

[40]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[41]  M. Edmonds,et al.  Increased osteoclastic activity in acute Charcot’s osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand , 2008, Diabetologia.

[42]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[43]  J. Adams,et al.  Osteopenia, Neurological Dysfunction, and the Development of Charcot Neuroarthropathy , 1995, Diabetes Care.